Renin-angiotensin-aldosterone system inhibitors, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are first-line therapies due to their benefits in reducing proteinuria and slowing CKD progression.[28] However, treatment resistance is common in CKD, requiring combination therapies and personalized approaches. The gene discussed is ACE; the disease is chronic kidney disease.